C Mang1, A Birkenmaier2, G Cathomas3, J Humburg4. 1. Department of Obstetrics and Gynecology, Bethesda Spital Basel, Gellertstrasse 144, 4052, Basel, Switzerland. claudia.mang@bethesda-spital.ch. 2. Department of Obstetrics and Gynecology, Bethesda Spital Basel, Gellertstrasse 144, 4052, Basel, Switzerland. 3. Institute of Pathology, Cantonal Hospital Baselland, Mühlemattstrasse 11, 4410, Liestal, Switzerland. 4. Department of Obstetrics and Gynecology, Bethesda Spital Basel, Gellertstrasse 144, 4052, Basel, Switzerland. joerg.humburg@bethesda-spital.ch.
Abstract
PURPOSE: Endometrial cancer can be divided into two types: endometrioid Type 1 (G1, G2) has a hormonal driven etiology, while Type 2 is more aggressive (G3 endometrioid, clear cell and serous cancer type) and estrogen independent. We noticed an increase of more aggressive G3 endometrioid endometrial adenocarcinomas. This observation is of relevance for daily clinical practice because therapy depends on the histopathological grading and myometrial invasion. G3 cancers or myometrial invasion of more than 50% should be hysterectomized including bilateral adnexectomy with pelvine and paraaortal lymphadenectomy. In G1/G2 and lower infiltration levels, hysterectomy with adnexectomy without lymphadenectomy is sufficient. METHODS: Data of the ASF Statistic were used to analyze the changes in the incidences of patients with endometrioid cancer, grading groups and their first diagnosed stages between 2006 and 2014. RESULTS: 2611 patients, with 243-341 women per year, were analyzed. The number of diagnosed G1 tumors increased from 25 to 37% and the G3 tumors from 18 to 32%, whereas the G2 cancers decreased from 58 to 31%. Despite the rise of G3 tumors, an increase in age at diagnosis was not observed. The proportions of initial diagnosed stages (FIGO I-IV) in each grading remained constant over time. CONCLUSION: Potential consequences in treatment recommendations and prognosis urge attention to the detected increase of G3 endometrioid cancers.
PURPOSE:Endometrial cancer can be divided into two types: endometrioid Type 1 (G1, G2) has a hormonal driven etiology, while Type 2 is more aggressive (G3 endometrioid, clear cell and serous cancer type) and estrogen independent. We noticed an increase of more aggressive G3 endometrioid endometrial adenocarcinomas. This observation is of relevance for daily clinical practice because therapy depends on the histopathological grading and myometrial invasion. G3 cancers or myometrial invasion of more than 50% should be hysterectomized including bilateral adnexectomy with pelvine and paraaortal lymphadenectomy. In G1/G2 and lower infiltration levels, hysterectomy with adnexectomy without lymphadenectomy is sufficient. METHODS: Data of the ASF Statistic were used to analyze the changes in the incidences of patients with endometrioid cancer, grading groups and their first diagnosed stages between 2006 and 2014. RESULTS: 2611 patients, with 243-341 women per year, were analyzed. The number of diagnosed G1 tumors increased from 25 to 37% and the G3 tumors from 18 to 32%, whereas the G2 cancers decreased from 58 to 31%. Despite the rise of G3 tumors, an increase in age at diagnosis was not observed. The proportions of initial diagnosed stages (FIGO I-IV) in each grading remained constant over time. CONCLUSION: Potential consequences in treatment recommendations and prognosis urge attention to the detected increase of G3 endometrioid cancers.
Entities:
Keywords:
Corpus uteri malignancy; Endometrial cancer; Endometrioid; G3
Authors: Cristina Anton; Rodolpho Truffa Kleine; Eric Mayerhoff; Maria Del Pilar Esteves Diz; Daniela de Freitas; Heloisa de Andrade Carvalho; João Paulo Mancusi de Carvalho; Alexandre Silva E Silva; Maria Luiza Nogueira Dias Genta; André Lopes de Faria E Silva; Rafael Calil Salim; Andrea Aranha; Rossana Veronica Mendoza Lopez; Filomena Marino Carvalho; Edmund Chada Baracat; Jesus Paula Carvalho Journal: PLoS One Date: 2020-03-05 Impact factor: 3.240